Extreme drug tolerance of mycobacterium tuberculosis in Caseum

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 2, 2018, Pages

  Sarathy, Jansy P ^a   Via, Laura E ^b,d   Weiner, Danielle ^b   Blanc, Landry ^a   Boshoff, Helena ^b   Eugenin, Eliseo A ^a,c   Barry, Clifton E ^b,d   Dartois, Véronique A ^a,c  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Caseum; Drug tolerance; In vitro potency model; Mycobacterium tuberculosis; Persistence; Pharmacokinetics pharmacodynamics

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERANCE; EX VIVO STUDY; IN VITRO STUDY; LEPORIDAE; MINIMUM BACTERICIDAL CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; DRUG EFFECT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG TOLERANCE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RABBITS; RIFAMYCINS; TUBERCULOSIS;

EID: 85041046554     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02266-17     Document Type: Article

References (57)

1. WHO. 2016. Global Tuberculosis Report. WHO, Geneva, Switzerland.
2. Horsburgh CR, Jr, Barry CE, III, Lange C. 2015. Treatment of tuberculosis. N Engl J Med 373:2149–2160. https://doi.org/10.1056/NEJMra1413919.
3. Dartois V. 2014. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12:159–167. https://doi.org/10.1038/nrmicro3200.
4. Sacchettini JC, Rubin EJ, Freundlich JS. 2008. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 6:41–52. https://doi.org/10.1038/nrmicro1816.
5. Nathan C, Barry CE, 3rd. 2015. TB drug development: immunology at the table. Immunol Rev 264:308–318. https://doi.org/10.1111/imr.12275.
6. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56:446–457. https://doi.org/10.1128/AAC.05208-11.
7. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O’Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE, III, Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21:1223–1227. https://doi.org/10.1038/nm.3937.
8. Aber VR, Nunn AJ. 1978. Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 53:276–280. (In French.)
9. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170:1124–1130. https://doi.org/10.1164/rccm.200407-905OC.
10. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. 2006. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 174:1153–1158. https://doi.org/10.1164/rccm.200605-637OC.
11. Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, Basaraba RJ, Lenaerts AJ. 2011. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6:e17550. https://doi.org/10.1371/journal.pone.0017550.
12. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, Orme IM, Basaraba RJ. 2007. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 51:3338–3345. https://doi.org/10.1128/AAC.00276-07.
13. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE, III, Flynn JL. 2012. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 109:14188–14193. https://doi.org/10.1073/pnas.1121497109.
14. Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E, Chen RY, Dodd LE, Richardson M, Robbins KK, Cai Y, Hammoud D, Herscovitch P, Dartois V, Flynn JL, Barry CE, 3rd. 2015. A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59:4181–4189. https://doi.org/10.1128/AAC.00115-15.
15. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE, III, Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83:2112–2118. https://doi.org/10.1021/ac1029049.
16. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231–S279.
17. Lipworth S, Hammond RJ, Baron VO, Hu Y, Coates A, Gillespie SH. 2016. Defining dormancy in mycobacterial disease. Tuberculosis (Edinb) 99: 131–142. https://doi.org/10.1016/j.tube.2016.05.006.
18. Gengenbacher M, Rao SP, Pethe K, Dick T. 2010. Nutrient-starved, nonreplicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156:81–87. https://doi.org/10.1099/mic.0.033084-0.
19. Loebel RO, Shorr E, Richardson HB. 1933. The influence of foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 26:139–166.
20. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062–2069.
21. Subbian S, Tsenova L, Yang G, O’Brien P, Parsons S, Peixoto B, Taylor L, Fallows D, Kaplan G. 2011. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol 1:110016. https://doi.org/10.1098/rsob.110016.
22. Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH. 24 March 2017. Acquisition of rifampin resistance in pulmonary tuberculosis. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.02220-16.
23. Lakshminarayana SB, Huat TB, Ho PC, Manjunatha UH, Dartois V, Dick T, Rao SP. 2015. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother 70:857–867. https://doi.org/10.1093/jac/dku457.
24. Sarathy JP, Zuccotto F, Ho H, Sandberg L, Via LE, Marriner GA, Masquelin T, Wyatt P, Ray P, Dartois V. 6 July 2016. Prediction of drug penetration in tuberculosis lesions. ACS Infect Dis https://doi.org/10.1021/acsinfecdis.6b00051.
25. Hammond RJH, Baron VO, Oravcova K, Lipworth S, Gillespie SH. 2015. Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you? J Antimicrob Chemother 70:2823–2827. https://doi.org/10.1093/jac/dkv178.
26. Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR. 2002. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 148:2951–2958. https://doi.org/10.1099/00221287-148-10-2951.
27. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, Hinds J, Rajakumar K, Adegbola RA, Besra GS, Butcher PD, Barer MR. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5:e75. https://doi.org/10.1371/journal.pmed.0050075.
28. Annam V, Kulkarni MH, Puranik RB. 2009. Comparison of the modified fluorescent method and conventional Ziehl-Neelsen method in the detection of acidfast bacilli in lymphnode aspirates. Cytojournal 6:13. https://doi.org/10.4103/1742-6413.53887.
29. Hung NV, Sy DN, Anthony RM, Cobelens FG, van Soolingen D. 2007. Fluorescence microscopy for tuberculosis diagnosis. Lancet Infect Dis 7:238–239, author reply 239–240. https://doi.org/10.1016/S1473-3099(07)70059-2.
30. Shapiro HM, Perlmutter NG. 2008. Killer applications: toward affordable rapid cell-based diagnostics for malaria and tuberculosis. Cytometry B Clin Cytom 74(Suppl 1):S152–S164. https://doi.org/10.1002/cyto.b.20401.
31. Sarathy JP, Liang HH, Weiner D, Gonzales J, Via LE, Dartois V. 8 May 2017. An in vitro caseum binding assay that predicts drug penetration in tuberculosis lesions. J Vis Exp doi:https://doi.org/10.3791/55559.
32. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, Pawar S, Rogers L, Kolattukudy PE. 2009. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 4:e6077. https://doi.org/10.1371/journal.pone.0006077.
33. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219–225. https://doi.org/10.1016/0041-3879(85)90040-6.
34. Canetti G. 1955. The tubercle bacillus. Springer Publishing Company, New York, NY.
35. Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, Demarco VP, Jain KK, Dartois V, Bishai WR, Dooley KE. Using the rabbit cavitary disease model, site-of-disease PK to understand rifamycin trial results for tuberculosis. Sci Transl Med, in press.
36. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577–1587. https://doi.org/10.1056/NEJMoa1407426.
37. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalam-bous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599 –1608. https://doi.org/10.1056/NEJMoa1314210.
38. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. 2010. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio 1:e00139-10. https://doi.org/10.1128/mBio.00139-10.
39. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939–949.
40. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6–21.
41. Gopal P, Dick T. 2014. Reactive dirty fragments: implications for tuberculosis drug discovery. Curr Opin Microbiol 21:7–12. https://doi.org/10.1016/j.mib.2014.06.015.
42. Lanoix JP, Lenaerts AJ, Nuermberger EL. 2015. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8:603–610. https://doi.org/10.1242/dmm.019513.
43. Lanoix JP, Ioerger T, Ormond A, Kaya F, Sacchettini J, Dartois V, Nuermberger E. 16 November 2015. Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01370-15.
44. Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ. 2016. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB/FeJ mice. ACS Infect Dis 2:251–267. https://doi.org/10.1021/acsinfecdis.5b00127.
45. Koller F, Leuthardt F. 1934. Nekrose und autolyse beitrag zur kenntnis der dystrophischen verkalkung. Klin Wochenschr 13:1527–1529. https://doi.org/10.1007/BF01779121.
46. Watanabe S, Zimmermann M, Goodwin MB, Sauer U, Barry CE, III, Boshoff HI. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog 7:e1002287. https://doi.org/10.1371/journal.ppat.1002287.
47. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42–49. https://doi.org/10.1099/0022-1317-51-1-42.
48. Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181:2044 –2049.
49. Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Tukvadze N, Little B, Bernheim A, Read TD, Guarner J, Derendorf H, Peloquin CA, Blumberg HM, Vashakidze S. 24 May 2017. Lung tissue concentrations of pyrazinamide among patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00226-17.
50. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. 2011. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 7:e1002093. https://doi.org/10.1371/journal.ppat.1002093.
51. Sloan DJ, Mwandumba HC, Garton NJ, Khoo SH, Butterworth AE, Allain TJ, Heyderman RS, Corbett EL, Barer MR, Davies GR. 2015. Pharmacody-namic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. Clin Infect Dis 61:1–8. https://doi.org/10.1093/cid/civ195.
52. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, Kolattukudy PE. 2004. Induction of a novel class of diacylglycerol acyltrans-ferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol 186:5017–5030. https://doi.org/10.1128/JB.186.15.5017-5030.2004.
53. Deb C, Daniel J, Sirakova TD, Abomoelak B, Dubey VS, Kolattukudy PE. 2006. A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem 281:3866–3875. https://doi.org/10.1074/ jbc.M505556200.
54. Baek SH, Li AH, Sassetti CM. 2011. Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol 9:e1001065. https://doi.org/10.1371/journal.pbio.1001065.
55. Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, Masquelin T, Wyatt P, Ray P, Dartois V. 2016. Prediction of drug penetration in tuberculosis lesions. ACS Infect Dis 2:552–563. https://doi.org/ 10.1021/acsinfecdis.6b00051.
56. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717–731. https://doi.org/10.1046/j.1365-2958.2002.02779.x.
57. Guan YQ, Cai YY, Zhang X, Lee YT, Opas M. 2008. Adaptive correction technique for 3D reconstruction of fluorescence microscopy images. Microsc Res Tech 71:146–157. https://doi.org/10.1002/jemt.20536.